Cutaneous B-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.
Alexandra C HristovTrilokraj TejasviRyan A WilcoxPublished in: American journal of hematology (2020)
Both PCFCL and PCMZL patients with solitary or relatively few skin lesions may be effectively managed with local radiation therapy. While single-agent rituximab may be employed for patients with more widespread skin involvement, multi-agent chemotherapy is rarely appropriate. In contrast, management of patients with PCDLBCL, LT is comparable to the management of patients with systemic DLBCL.